These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31727629)

  • 1. Prophylactic
    Li C; Course MM; McNeish IA; Drescher CW; Valdmanis PN; Lieber A
    Cancer Res; 2020 Feb; 80(3):549-560. PubMed ID: 31727629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.
    Ben Nasr M; Tezza S; D'Addio F; Mameli C; Usuelli V; Maestroni A; Corradi D; Belletti S; Albarello L; Becchi G; Fadini GP; Schuetz C; Markmann J; Wasserfall C; Zon L; Zuccotti GV; Fiorina P
    Sci Transl Med; 2017 Nov; 9(416):. PubMed ID: 29141886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors.
    Richter M; Saydaminova K; Yumul R; Krishnan R; Liu J; Nagy EE; Singh M; Izsvák Z; Cattaneo R; Uckert W; Palmer D; Ng P; Haworth KG; Kiem HP; Ehrhardt A; Papayannopoulou T; Lieber A
    Blood; 2016 Nov; 128(18):2206-2217. PubMed ID: 27554082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements.
    Wang H; Georgakopoulou A; Li C; Liu Z; Gil S; Bashyam A; Yannaki E; Anagnostopoulos A; Pande A; Izsvák Z; Papayannopoulou T; Lieber A
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.
    Wang H; Georgakopoulou A; Psatha N; Li C; Capsali C; Samal HB; Anagnostopoulos A; Ehrhardt A; Izsvák Z; Papayannopoulou T; Yannaki E; Lieber A
    J Clin Invest; 2019 Feb; 129(2):598-615. PubMed ID: 30422819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Delivery of an Adenoviral Vector Carrying the
    Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
    Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.
    Morton JJ; Keysar SB; Perrenoud L; Chimed TS; Reisinger J; Jackson B; Le PN; Nieto C; Gomez K; Miller B; Gao D; Somerset H; Wang XJ; Jimeno A
    Mol Carcinog; 2018 Nov; 57(11):1651-1663. PubMed ID: 30129680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
    Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
    MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source.
    Hess NJ; Lindner PN; Vazquez J; Grindel S; Hudson AW; Stanic AK; Ikeda A; Hematti P; Gumperz JE
    Front Immunol; 2020; 11():573406. PubMed ID: 33193358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
    Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
    Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
    Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
    Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.
    Persson J; Beyer I; Yumul R; Li Z; Kiem HP; Roffler S; Lieber A
    PLoS One; 2011; 6(7):e22303. PubMed ID: 21779410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
    Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
    Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.
    Li C; Mishra AS; Gil S; Wang M; Georgakopoulou A; Papayannopoulou T; Hawkins RD; Lieber A
    Mol Ther; 2019 Dec; 27(12):2195-2212. PubMed ID: 31494053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
    Ahmad G; Mackenzie GG; Egan J; Amiji MM
    Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
    Hong W; Xue M; Jiang J; Zhang Y; Gao X
    J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.